- Home
- NTLA vs OPK Comparison
NTLA vs OPK Comparison
Compare NTLA & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- OPK
- Stock Information
- Founded
- NTLA 2014
- OPK 2007
- Country
- NTLA United States
- OPK United States
- Employees
- NTLA N/A
- OPK N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- OPK Biotechnology: Pharmaceutical Preparations
- Sector
- NTLA Health Care
- OPK Health Care
- Exchange
- NTLA Nasdaq
- OPK Nasdaq
- Market Cap
- NTLA 1.2B
- OPK 1.1B
- IPO Year
- NTLA 2016
- OPK 1995
- Fundamental
- Price
- NTLA $13.60
- OPK $1.37
- Analyst Decision
- NTLA Buy
- OPK Buy
- Analyst Count
- NTLA 19
- OPK 4
- Target Price
- NTLA $35.11
- OPK $2.75
- AVG Volume (30 Days)
- NTLA 4.7M
- OPK 2.6M
- Earning Date
- NTLA 08-07-2025
- OPK 08-06-2025
- Dividend Yield
- NTLA N/A
- OPK N/A
- EPS Growth
- NTLA N/A
- OPK N/A
- EPS
- NTLA N/A
- OPK N/A
- Revenue
- NTLA $45,569,000.00
- OPK $689,408,000.00
- Revenue This Year
- NTLA N/A
- OPK N/A
- Revenue Next Year
- NTLA N/A
- OPK $6.98
- P/E Ratio
- NTLA N/A
- OPK N/A
- Revenue Growth
- NTLA N/A
- OPK N/A
- 52 Week Low
- NTLA $5.90
- OPK $1.21
- 52 Week High
- NTLA $27.42
- OPK $2.04
- Technical
- Relative Strength Index (RSI)
- NTLA 65.69
- OPK 51.75
- Support Level
- NTLA $12.48
- OPK $1.34
- Resistance Level
- NTLA $14.61
- OPK $1.45
- Average True Range (ATR)
- NTLA 0.90
- OPK 0.05
- MACD
- NTLA 0.13
- OPK 0.00
- Stochastic Oscillator
- NTLA 76.33
- OPK 38.46
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.